XML 63 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Summary of Significant Accounting Policies (Details)
3 Months Ended
Apr. 03, 2020
USD ($)
segment
product
$ / shares
Mar. 29, 2019
USD ($)
$ / shares
Jan. 03, 2020
USD ($)
Organization And Summary Of Significant Policies [Line Items]      
Number of business segments | segment 1    
Selling, general and administrative $ 62,940,000 $ 60,138,000  
Decrease in earnings per share due to change in accounting estimate (USD per share) | $ / shares $ (0.16) $ (0.25)  
Decrease in earnings per share diluted, due to change in accounting estimate (USD per share) | $ / shares $ (0.15) $ (0.24)  
Branded Prescription Drug Fee, accrual $ 13,400,000   $ 6,000,000.0
Branded Prescription Drug Fee, accrual, current 8,600,000   4,400,000
Branded Prescription Drug Fee, accrual, noncurrent 4,800,000   $ 1,600,000
Goodwill impairment $ 0    
Resulting from Discovery Efforts      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 4    
Products Derived from Cabozantinib      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 2    
Products Derived From Other Compounds      
Organization And Summary Of Significant Policies [Line Items]      
Number of products that entered in the commercial marketplace | product 2    
New Information [Member]      
Organization And Summary Of Significant Policies [Line Items]      
Selling, general and administrative $ 5,400,000    
Decrease in earnings per share due to change in accounting estimate (USD per share) | $ / shares $ 0.02    
Decrease in earnings per share diluted, due to change in accounting estimate (USD per share) | $ / shares $ 0.02